ALUNBRIG® (brigatinib) Shrank Tumors in Patients with ALK+ NSCLC That Had Spread to Other Parts of the Body

ALUNBRIG was evaluated in a broad range of patients, including those with ALK+ NSCLC that had spread to other parts of their body

The ALUNBRIG study included 275 patients with ALK+ NSCLC whose cancer had spread to other parts of their body.

137 patients received the recommended dosing regimen of 90 mg of ALUNBRIG orally once daily for 7 days, followed by an increase to 180 mg orally once daily. The other 138 patients received a different medicine called crizotinib.

  • Patient ages ranged from 27 years to 89 years (average age was 59 years) and about half (55%) were female
  • 58% of patients in the study had never smoked

Patients taking ALUNBRIG went twice as long without their disease getting worse or spreading versus those taking crizotinib

  • BLINDED INDEPENDENT REVIEW COMMITTEE RESULTS

MEDIANa TIME TO PROGRESSION
Bar chart showing that the median time to progression for patients taking ALUNBRIG was 24 months versus 11 months for patients taking crizotinib.

aMedian is not the same as average. Please see glossary for definition.

  • BLINDED INDEPENDENT REVIEW COMMITTEE
    This was a group of independent researchers who objectively reviewed and evaluated the results from the trial.

OVERALL

Overall 3 out of 4 patients had their tumor shrink in people taking ALUNBRIG (74%) versus crizotinib (62%).

Overall, 3 out of 4 patients had their tumors shrink in people taking ALUNBRIG (74%) versus crizotinib (62%).

101 of 137 patients (74%) taking ALUNBRIG achieved a response vs 85 of 138 patients (62%) taking crizotinib.

ALUNBRIG Helped Shrink Tumors in the Brain

The Blinded Independent Review Committee also evaluated a smaller group of 41 patients with brain metastases.

Overall, 14 of 18 patients (78%) achieved a response while taking ALUNBRIG vs 6 of 23 patients (26%) taking crizotinib

  • 3 out of every 4 patients with cancer that spread to their brain saw their tumors shrink when they were treated with ALUNBRIG


Of the 14 patients in this smaller group who responded to treatment with ALUNBRIG...

More than half of all patients (9 out of 14) who responded to ALUNBRIG maintained that response for 2 years or longer

  • Researchers could not estimate the results for the 6 patients who responded to treatment with crizotinib

People Reported a Better Quality of Life with ALUNBRIG

During the study, 131 people taking ALUNBRIG completed a quality of life questionnaire.

Results from the questionnaire showed that people receiving ALUNBRIG went THREE TIMES LONGER without the symptoms of their cancer getting worse compared to patients treated with crizotinib.

  • This means that the average time to symptoms getting worse was 26.7 months for patients taking ALUNBRIG compared with 8.3 months for patients taking crizotinib
  • The study measurement included how people functioned with the disease (physical, emotional and social functioning) and the severity of the symptoms they experienced (including fatigue, nausea, vomiting, appetite loss and constipation)

Every patient is different. Always talk to your doctor
if you have any questions about ALUNBRIG.


How to Take ALUNBRIG

Glossary

Median-The middle number in a set of measurements arranged from lowest to highest.

The middle number in a set of measurements arranged from lowest to highest.


ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

ALUNBRIG(TM) BRIGATINIB 39 mg TABLETS

This site is intended for residents of the US and US territories only.

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue +

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue +

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel +

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.


 
 
 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More